NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

TSX · Biotechnology · CAD

Resverlogix Corp. (RVX.TO) Stock Analysis

Resverlogix Corp. (RVX.TO) is a Biotechnology stock listed on TSX and quoted in Canadian Dollar.

RVX.TO

CA$0.10

CA$0.00 (0.00%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare RVX.TO with… →

RVX.TO Key Statistics

As of Sep 4, 2026
Trading
Open
CA$0.10
Previous Close
CA$0.10
52-Week Range
0.09–0.15
Volume
600
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.05
Valuation
Market Cap
CA$32.71M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.06
Financials (FY)
Revenue (FY)
CA$0.00
Net Income (FY)
−CA$7.77M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
344.29M
1-Year Return
+0.00%
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
25.63K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

RVX.TO Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+0.00%
2025+66.67%
2024−14.29%
2023−50.00%
2022−72.55%
2021−45.74%
2020−23.58%
2019−62.61%
2018+60.49%
2017+20.59%
2016 (partial year)+45.30%

As of September 4, 2026.

RVX.TO Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025CA$0.00−CA$7.77M—
2024CA$0.00−CA$7.64M—
2023CA$0.00−CA$16.74M—
2022CA$0.00−CA$3.61M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025CA$0.00—−CA$5.06M−CA$7.77M—
2024CA$0.00—−CA$4.60M−CA$7.64M—
2023CA$0.00—−CA$6.21M−CA$16.74M—
2022CA$0.00—−CA$12.71M−CA$3.61M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

RVX.TO Valuation vs Biotechnology Median

Median of 656 stocks
MetricRVX.TOBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

The market values Resverlogix Corp. (RVX.TO) at CA$32.71M. The company sits in the Healthcare sector, in the Biotechnology industry.

RVX.TO last closed at CA$0.10 on September 4, 2026. The close was unchanged from the previous session. The 52-week range on file runs from CA$0.09 to CA$0.15. The latest close sits 11.11% above that 52-week low.

Financial Health

In fiscal 2025, Resverlogix Corp. reported revenue of CA$0.00. The same year closed with a net loss of CA$7.77M. Profit margin runs at 0%. Trailing earnings per share are −0.06.

Across the 4 fiscal years on file, revenue moves from CA$0.00 in 2022 to CA$0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The trailing one-year price return is 0.00%. Across 10 years the annualized return works out at −22.26%. Beta against the wider market is reported at 1.05. Daily returns over the trailing 10 years annualize to a volatility of 103.08%.

Growth & Income

The record shows no dividend for RVX.TO.

2026 is still running; the price is 0.00% year to date. The strongest complete calendar year on file is 2025 at +66.67%; the weakest is 2022 at −72.55%. Of the 9 complete calendar years on file, 3 finished higher.

Peer Comparison

Resverlogix Corp. (RVX.TO) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Resverlogix Corp. RVX.TO CA$32.71M —
Vertex Pharmaceuticals Incorporated VRTX CA$138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN CA$85.22B 20.5
argenx SE ARGX CA$64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Resverlogix Corp. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Resverlogix Corp.

Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein, recent acute coronary syndrome, and post COVID-19 conditions. The company has a partnership with Eversana Life Science Services, LLC to support the commercialization of apabetalone for COVID-19 in the United States and Canada; developing cardiovascular and pulmonary arterial hypertension indications; and Medison Pharma Ltd. The company is headquartered in Calgary, Canada.

Visit website →